Cite
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.
MLA
Perreault, Leigh, et al. “Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 Mg Among Participants With Prediabetes in the STEP Program.” Diabetes Care, vol. 45, no. 10, Oct. 2022, pp. 2396–405. EBSCOhost, https://doi.org/10.2337/dc21-1785.
APA
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2022). Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care, 45(10), 2396–2405. https://doi.org/10.2337/dc21-1785
Chicago
Perreault, Leigh, Melanie Davies, Juan P Frias, Peter Nørkjaer Laursen, Ildiko Lingvay, Sriram Machineni, Anette Varbo, John P H Wilding, Signe Olrik Rytter Wallenstein, and Carel W le Roux. 2022. “Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 Mg Among Participants With Prediabetes in the STEP Program.” Diabetes Care 45 (10): 2396–2405. doi:10.2337/dc21-1785.